This technology allows phenotypic screening to discover new compounds and new targets for complex diseases, such as neurodegenerative diseases and cancer
HCS main assets for active cosmetic ingredients
Confirming the efficacy of nutraceuticals and functional food is a key for the development of new compounds. High content in vitro assays play a role in researching and developing new actives ingredients dedicated to human and animals food.
Phenotypic screening by High Content Screening allows analysing toxic events, as genotoxicity, hepatotoxicity, neurotoxicity or cardiotoxicity at the early stage of research.
BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
Employeur : HCS Pharma Lieu de travail : Rennes Statut : Cadre Poste : Technico-commercial / Business Developer Rémunération : selon expérience Contexte HCS Pharma est une entreprise de services en biotechnologie créée en aout 2014, Read more…
Employeur : HCS Pharma Lieu de travail : Rennes Statut : Cadre Poste : Chef de projet cosmétologie / dermocosmétique Rémunération : selon expérience Contexte HCS Pharma est une entreprise de services en biotechnologie créée en Read more…
Every year, the CES (Consumer Electronics Show) in Las Vegas is the major meeting for technological innovations for consumer market. This year, many companies (more than 600) presented products and services in the healthcare domain Read more…
The European Center of Dermocosmetology is a french professional association dedicated to the promotion of a high level of education in cosmetology and dermatology. This year, the “Journées Européenes de Dermocosmétologie” will focus on the Read more…
Review of Human neuro-astrocytes 3D co-culture-based assay for evaluation of neuroprotective compounds (Terrasso et al. 2017) Terrasso et al. published a study about a neuroprotection assay on a 3D model in 2017. They developed a Read more…
Cosmetagora is organized by the "Société Française de Cosmetologie" and is one of the major french event in terms of cosmetic formulation. Our study director Pierre-Jean and our business developer Nathalie Accornero will be present during the two days of the event.
We are very happy to wish you a wonderful year 2019! Nous sommes très heureux de vous souhaiter une excellente année 2019 !
On November 7th, the 10th revision of the SCCS’s Notes of Guidance has been released. If you work in cosmetology, you know the importance of this document used to “provide guidance to public authorities and Read more…
Sood et al. published in 2016 an interesting article about the effect of extracellular matrix (ECM) on in vitro neuronal cells culture: “Fetal brain extracellular matrix boosts neuronal network formation in 3D bioengineered model of Read more…
Our study directors Elodie and Pierre-Jean enjoyed the last edition of Health Ingredients Europe, which took place in Frankfurt (Germany) from the 27th to the 28th of November 2018. For their first time in HIE, Read more…
HCS Pharma team enjoyed attending BioFit 2018 and hosted events in Lille last week! Our business developer Nathalie had many fruitful BtoB meetings along the convention, and our study director Elodie could meet lots of Read more…
We are developing a new BIOMIMESYS® hydroscaffold for neuronal cells. First results are very promising because neurons grow and form neurites. Moreover cells lived longer than in monolayer culture. We are currently finalizing this new Read more…
We will be happy to meet you on Biofit, Lille, France, on December 4th & 5th, 2018 at the business convention or on our Booth D4/2 on Eurasanté/pole NSL Pavillion located at the center of Read more…
Now, life science companies are seeking ways to modernise research environments and build the ‘Lab of The Future’ (LoTF). Given advances made in recent years, it’s natural that technology that can automate lab functions – Read more…
Our study directors Elodie and Pierre-Jean will attend “HI Europe” in Frankfurt next week. We cordially invite you to discuss with them, they will be happy to present our imaging services related to nutraceutical testing! We Read more…
The status of Young Innovative Company (JEI) recognize young companies very active in R&D. this distinction is given by the french ministry of research.
Led by Pr Bertrand Cariou, director of l’institut du thorax*, the project aims at improving the management of hypercholesterolemia by identifying new markers in cardiovascular risk and new targets of LDL-cholesterol metabolism, which plays a central role in the development and progression of cardiovascular diseases.
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
HCS Pharma – Site de Rennes
Biopole
6 Rue Pierre Joseph Colin
35000 RENNES
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.